Eli Lilly and Company (LLY) Stock

NYSE
HealthcareDrug Manufacturers - General Website

LLY has an Alpha Score of 61 out of 100 (moderate), computed on Nov 13, 2026 from 3 of 4 sub-scores. 45 members of Congress disclosed 159 trades in LLY since 2014: 74 purchases and 85 sales, most recently Michael Rulli (partial sale, Nov 4, 2026). 7 of the hedge funds AlphaScala tracks reported LLY in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Citadel's at $788.53M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 20, 2026. Its trailing P/E ratio is 46.2 and its net margin 31.9% (key statistics as of Nov 8, 2026).

$1347.11
-0.30%
Last price
Source: Finnhub
Alpha Score
61
Moderate

What is LLY's Alpha Score?

How it works →

Alpha Score of 61 reflects moderate overall profile with strong momentum, poor value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
94
Strong
Value
16
Poor
Quality
87
Strong

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 13, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Eli Lilly and Company (LLY)?

Members
45
Disclosed trades
159
Purchases
74
Sales
85

Most recent: Michael Rulli (partial sale, Nov 4, 2026); records start Feb 5, 2014.

PoliticianTrade dateTypeAmount
Michael Rulli
R-OH · House
2026-11-04partial sale$1k – $15k
Dave Taylor
R-OH · House
2026-11-03sale$1k – $15k
Gil Cisneros
D-CA · House
2026-10-20purchase$1k – $15k
Dan Newhouse
R-WA · House
2026-07-10partial sale$1k – $15k
Michael Rulli
R-OH · House
2026-07-01sale$1k – $15k
Gil Cisneros
D-CA · House
2026-06-10purchase$50k – $100k
Gil Cisneros
D-CA · House
2026-04-14purchase$1k – $15k
Lizzie Fletcher
D-TX · House
2026-04-08partial sale$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

Every member of Congress who traded LLY, with filing lags →

Which hedge funds own LLY?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Citadel
Ken Griffin
681K$788.53M-28%
D.E. Shaw
David Shaw
316K$366.08M-36%
Marshall Wace223K$258.18M-33%
Millennium Management
Israel Englander
200K$231.34M+9%
Point72
Steve Cohen
116K$133.78M+1004%
ARK Invest
Cathie Wood
108K$124.78M+40%
Bridgewater Associates
Ray Dalio
95K$109.60M+9%

13F holdings as of Sep 30, 2026

Explore all tracked funds →

Are Eli Lilly and Company insiders buying or selling?

SEC Form 4 filings
90 days to Nov 20, 2026
Buys
0
Sells
1
Net $
-$7.0M
Unique insiders
1
DateInsiderRoleTypeSharesValue
Nov 2, 26Hakim AnatEVP, GC & SecretarySELL5.0K$7.0M
Aug 17, 26Jonsson PatrikEVP & President, LLY Int'lSELL6.5K$7.6M
Aug 10, 26Zakrowski Donald ASVP, Finance, & CAOSELL2.0K$2.4M
Aug 7, 26Hakim AnatEVP, GC & SecretarySELL5.0K$6.0M

SEC Form 4 filings as of Nov 20, 2026

See cluster-buy signals across all tickers →

What are LLY's key statistics?

P/E Ratio
46.19
EPS (TTM)
30.81
Dividend Yield
0.75%
Beta
0.39
Net Margin
31.90%
ROE
83.65%
Debt / Equity
1.60
52W High
$1453.00
52W Low
$850.51

Key statistics as of Nov 8, 2026

How does LLY's valuation compare with the Healthcare sector?

MetricLLYHealthcare medianCompanies in median
P/E ratio46.229.1147
Net margin31.90%3.59%223
Return on equity83.65%3.41%255
Dividend yield (payers)0.75%1.37%61

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 22, 2026). P/E excludes loss-making companies.

What did Eli Lilly and Company's latest SEC filings say?

Latest 2
10-KFeb 12, 2026SEC.gov →

Eli Lilly 10-K Filing Reports Financial Results and Strategic Asset Portfolio Activity for 2025

Eli Lilly and Company filed its 10-K for the fiscal year ended December 31, 2025. The filing details the company's financial position, including its debt structure with various notes maturing between 2026 and 2061. The company maintains significant product concentration in its cardiometabolic, oncology, immunology, and neuroscience segments. Key products highlighted include Mounjaro, Zepbound, Trulicity, Jardiance, Verzenio, and Taltz. The company reports customer concentration risk related to its three largest wholesalers. The filing also outlines recent corporate activity, including investments and acquisitions involving Verve Therapeutics, SiteOne Therapeutics, Scorpion Therapeutics, Morphic Holding, and others. The company continues to manage its portfolio through divestitures, such as the previous sale of the Olanzapine portfolio and Baqsimi. Financial disclosures include fair value measurements for marketable securities and debt instruments.

Material changes
  • ›Reported ongoing financial activity across key product lines including Mounjaro, Zepbound, and Jardiance.
  • ›Disclosed customer concentration risk involving the company's three largest wholesalers.
  • ›Detailed debt maturity schedule for notes ranging from 2026 to 2061.
  • ›Confirmed strategic investments and acquisitions in 2025 including Verve Therapeutics, SiteOne Therapeutics, and Scorpion Therapeutics.
  • ›Maintained reporting on divestiture impacts from the sale of the Olanzapine portfolio and Baqsimi.
8-KFeb 4, 2026SEC.gov →

Eli Lilly Files Form 8-K to Announce Fourth Quarter and Full Year Results

Eli Lilly and Company filed a Form 8-K on February 4, 2026, to formally announce its financial results for the quarter and the full fiscal year ended December 31, 2025. The filing serves as a procedural notification regarding the release of the company's earnings performance. The actual financial data, including revenue, earnings per share, and management commentary, is contained within Exhibit 99.1, which is a press release issued by the company on the same date. Per the filing, the information provided under Item 2.02 is furnished and not deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934. This means the information is not subject to the liabilities of that section and is not incorporated by reference into other registration statements or documents filed under the Securities Act of 1933 or the Exchange Act, unless explicitly stated otherwise by the company in future filings.

Material changes
  • ›Company announced financial results for the quarter and year ended December 31, 2025.
  • ›Financial results were provided via an attached press release labeled Exhibit 99.1.
  • ›The filing confirms the company's compliance with reporting requirements under the Securities Exchange Act of 1934.

LLY price chart

Powered by TradingView

What does Eli Lilly and Company do?

Eli Lilly and Company is a leading pharmaceutical company engaged in the discovery, development, manufacture, and sale of human pharmaceutical products. It focuses on innovative medicines addressing critical health needs in areas such as diabetes, oncology, immunology, neuroscience, obesity, cardiovascular diseases, cancer, and other therapeutic categories including bone muscle joint disorders, endocrine conditions, dermatology, autoimmune diseases, sleep apnea, migraine, and Alzheimer's disease. The company offers treatments like insulins, GLP-1 therapies for diabetes and obesity, oncology drugs, immunologic agents, and neuroscience products. Eli Lilly and Company supports access initiatives through partnerships for technology transfer and API supply to manufacturers in low- and middle-income countries, enhancing availability of insulins and other therapies in regions like Africa and Bangladesh. It maintains a robust research and development pipeline targeting non-communicable diseases, with late-stage projects in diabetes, cardiovascular, and oncology areas. Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly and Company plays a significant role in the global health technology sector by delivering therapies that improve patient outcomes across diverse medical fields.

CEO
Mr. David A. Ricks
Employees
50,000
Market Cap
$1.27T
Ask about LLYAI research agent